The Prescription Justice Board of Directors recently approved a statement regarding Covid-19. The Board recognizes that Covid-19 infuses the crisis of high drug prices with greater life-and-death urgency.
Gabriel Levitt, President of Prescription Justice submitted comments to the Food and Drug Administration (FDA) in response to the Notice of Proposed Rulemaking (NPRM) titled "Importation of Prescription Drugs, FDA-2019-N-5711, 84 Fed. Reg. 70796.
Prescription Justice is proud to announce that a statement prepared by PJ President Gabriel Levitt for the U.S. House Ways and Means Committee on “Investing In The U.S. Health System By Lowering Drug Prices, Reducing, Out-of-Pocket Costs and Improving the Medicare Benefit” is now part of the official congressional record.
Elizabeth, who is from California, periodically gets migraine headaches. To treat them, she is prescribed brand name Relpax (elitriptan), but finds that the drug is too expensive in the U.S., so she chooses to import the same drug at a much lower price. Despite federal restrictions, most medicines that are imported for personal use reach the patient. But not always. In Elizabeth’s case, instead of receiving her medication, the Food and Drug Administration (FDA) destroyed the medication after it was detained at an international mail facility (IMF). She gave Prescription Justice the green light to tell her story.
Founder of Prescription Justice, Gabriel Levitt, submitted a public comment to the World Health Organization (WHO) on the role of personal importation and online access to safe and affordable medicine in meeting the UN Sustainable Development Goals. The Global Action Plan for Healthy Lives and Well-Being for All is a joint initiative led by twelve global health and development organizations under the auspices of the WHO.